Plant Name: Salta triflora
Taxonomic Information:
Plant ID: NPO11119
Plant Latin Name: Salta triflora
Taxonomy Genus: Salta
Taxonomy Family: Polygonaceae
Plant External Links:
NCBI TaxonomyDB:
249117
Plant-of-the-World-Online:
77116653-1
Used in Medicines:
Unknown.
Geographical Distribution:
Brazil; Bolivia
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| NPSR1; | |
| ACHE; | |
| MET; AXL; FLT3; CDK1; PIM1; KDR; IGF1R; AURKB; | |
| CA12; CA9; CA7; CA4; | |
| ALOX12; GFER; HSD17B10; NOX4; POLB; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 2 | CYP2A13 | Cytochrome P450 2A13 | Q16696 | CHEMBL3542436 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | GFER | FAD-linked sulfhydryl oxidase ALR | P55789 | CHEMBL1741189 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
| Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
| Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
| Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
| Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
| Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
| Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.708E-09 | 1.859E-05 | CA12, CA4, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 7.256E-08 | 1.975E-04 | CA12, CA4, CA7, CA9 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 1.662E-07 | 3.970E-04 | CA12, CA4, CA7, CA9 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.823E-07 | 3.970E-04 | CYP1A2, CYP1B1, CYP2A13, NOX4 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 1.683E-06 | 1.698E-03 | CYP1A2, CYP1B1, CYP2A13 |
| BP | GO:0008152; metabolic process | GO:0018108; peptidyl-tyrosine phosphorylation | 1.809E-06 | 1.712E-03 | AXL, FLT3, IGF1R, KDR, MET |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 2.238E-06 | 1.874E-03 | CYP1A2, CYP1B1, CYP2A13 |
| BP | GO:0008152; metabolic process | GO:0046777; protein autophosphorylation | 2.339E-06 | 1.887E-03 | AURKB, FLT3, IGF1R, KDR, PIM1 |
| BP | GO:0008152; metabolic process | GO:0072593; reactive oxygen species metabolic process | 4.983E-06 | 3.288E-03 | ALOX12, CYP1A2, CYP1B1, NOX4 |
| BP | GO:0065007; biological regulation | GO:0042592; homeostatic process | 9.105E-06 | 5.358E-03 | ALOX12, AXL, CA12, CA7, FLT3, MET, NOX4, NPSR1, POLB |
| MF | GO:0005488; binding | GO:0020037; heme binding | 1.227E-05 | 6.516E-03 | CYP1A2, CYP1B1, CYP2A13, NOX4 |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 2.588E-09 | 1.579E-07 | CA12, CA4, CA7, CA9 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 6.835E-05 | 1.966E-03 | CYP2A13, CYP1A2, CYP1B1 |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 9.670E-05 | 1.966E-03 | CYP2A13, CYP1A2, CYP1B1 |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 8.784E-04 | 9.631E-03 | CYP1A2, CYP1B1 |
| 09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 1.376E-03 | 9.631E-03 | KDR, MET, IGF1R |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04510 | Focal adhesion | 1.357E-03 | 9.631E-03 | KDR, MET, IGF1R |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 1.370E-03 | 9.631E-03 | CYP1B1, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05202 | Transcriptional misregulation in cancer | 9.734E-04 | 9.631E-03 | FLT3, MET, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04015 | Rap1 signaling pathway | 1.537E-03 | 9.631E-03 | KDR, MET, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04014 | Ras signaling pathway | 1.895E-03 | 9.631E-03 | KDR, MET, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05221 | Acute myeloid leukemia | 1.777E-03 | 9.631E-03 | FLT3, PIM1 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 1.839E-03 | 9.631E-03 | CYP1A2, CYP1B1 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R; |
| K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET; |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | AURKB; FLT3; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; |
| C00-D49: Neoplasms | Ovarian cancer | C56 | KDR; |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | KDR; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; ACHE; |
| C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9; |
| C00-D49: Neoplasms | CLL | NA | FLT3; |
| C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; |
| C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | NPSR1; |
| C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR; |
| C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; |
| C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR; |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3; |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; |
| C00-D49: Neoplasms | Gastric cancer | C16 | KDR; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | MET; AURKB; IGF1R; KDR; FLT3; CA9; |
| C00-D49: Neoplasms | Metastasis | C00-C97 | AXL; |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; |
| C00-D49: Neoplasms | Multiple myeloma | C90 | IGF1R; |
| G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | CDK1; IGF1R; ACHE; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | KDR; FLT3; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
| NA: NA | Upper abdominal bloating | NA | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
| C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR; |
| C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; |
| C00-D49: Neoplasms | Prostate cancer | C61 | FLT3; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R; |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9; |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3; |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | IGF1R; KDR; FLT3; |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; IGF1R; KDR; AXL; |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR; |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
| I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR; |
| I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET; |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; |
| C00-D49: Neoplasms | Renal cancer | C64 | KDR; CA9; |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3; |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R; |
| H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R; |
| C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR; |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR; |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; |
| NA: NA | GIST | NA | FLT3; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3; |
| C00-D49: Neoplasms | Glioma | C71 | KDR; |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
| C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET; |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3; |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | AURKB; |
| C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; |
| C00-D49: Neoplasms | Breast cancer | C50 | CDK1; IGF1R; KDR; FLT3; CA9; |
| C00-D49: Neoplasms | AML | NA | KDR; FLT3; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; |
| C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR; |
| C00-D49: Neoplasms | Melanoma | C43 | KDR; |
| C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR; |
| C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR; |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3; |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; |
| C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
| C00-D49: Neoplasms | Cancer | C00-C96 | PIM1; MET; CDK1; IGF1R; KDR; FLT3; ACHE; CA9; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
